With Eli Lilly, a major player in the pharmaceutical industry, showing interest in Bioage Labs, I see a strong opportunity for growth in BIOA. The relationship hints at potential advancements in weight loss products, making it a solid choice for an upward movement in the near term.

I'm really bullish on BioAge right now. They're starting trials that combine their azelaprag with popular weight loss drugs, which could unlock a massive market. With their promising results and increasing attention on weight loss solutions, I feel confident in taking a swing position on this one.